11519 RESULTS
COMMENT Belur et al. report a novel consequence of nuclear synuclein oligomers, namely the accumulation of NONO and SFPQ, leading to aberrant editing of Alu elements and the formation of novel inclusions in SNCA p.A53T ISPC lines. There is prior evidence that nuc
COMMENT This is a well-done and surprising study, indicating a new form of protein inclusion in PD and synucleinopathy patients, namely, nuclear aggregates consisting of RNA-editing proteins and/or two RNA-binding proteins. The formation of these impressively lar
COMMENT Quanterix welcomes FDA oversight of lab-developed tests as an important step toward broadening the acceptance and implementation of blood-based biomarkers in Alzheimer’s. As has been stated by others in this forum, there have been a plethora of new tests
COMMENT Dennis Selkoe’s article in Nature Aging is an informative and unbiased account of a very complicated subject. He provides a well-written description of the amyloid problem and a convincing assessment of anti-amyloid treatment as being a realistic option f
COMMENT We have about 30 patients on lecanemab at present, including a small handful now beyond six months of treatment. For most, the process has been fairly smooth. Insurance coverage denials fortunately have been rare, but when they have occurred, have been st
COMMENT Since January, we have gone from about 20 clinic patients on leqembi to about 40. By the numbers, therefore, the rate of enrollment over the past four months has not clearly accelerated since the close of 2023. This might be a little misleading, as it is
COMMENT We submitted a late-breaking abstract to AAIC summarizing our experience. In brief, we are treating more patients now than at the beginning of this year. Wait times from the decision to actually start drug are quite brief, perhaps a few weeks in general n
COMMENT DeCarli et al. provide evidence for secular trends in intracranial volume, white- and gray-matter volume, hippocampal volume, and cortical surface area for birth cohorts from 1930 to 1970. Although ICV is established fairly early in life and does not chan
COMMENT The new regulations of diagnostic Alzheimer´s disease tests by the U.S. FDA are an important step to increase the accuracy of the tests. The stratification of patients with neurodegeneration is crucial for a positive therapy response, as already seen for
COMMENT In this work, Slemann and colleagues utilized tau-transgenic mice and brain sections derived from PSP patients who had undergone PET scans, along with sections from a brain bank, to demonstrate the ability of a tau PET probe, 18F PI2620, to capture four-r
COMMENT Like other tau PET tracers, for example MK6240, flortaucipir, and RO948, PI2620 has shown excellent diagnostic performance in distinguishing symptomatic AD from other neurodegenerative disorders. An open question is whether PI2620 can also be utilized for
COMMENT 18F PI-2620 was developed to image aggregated tau with mixed 3- and 4-microtuble-binding repeat domains (3R- and 4R-tau) in patients with Alzheimer’s disease (AD), and has recently been applied to patients with 4R-tauopathies, such as progressive supranuc
COMMENT The findings of height-, age-, and sex-independent increases in intracranial, hippocampal, and white-matter volumes and in cortical surface area in members of the Framingham Heart Study born over successive decades are fascinating and suggest that changin
COMMENT The FDA's decision to impose stricter regulations on in vitro "diagnostic" tests was anticipated, and this regulatory change will be beneficial for the Alzheimer's in vitro test ecosystem, as well as for clinicians and their patients.
COMMENT TGFꞵ1 is well-established as a contributor to cerebral amyloid angiopathy (CAA) (Wyss-Coray et al., 1997), and one of the earliest actions noted for TGFꞵ was induction of fibronectin expression (Ignotz and Massagué, 1986). It seems quite likely that this
